Citi: Lowers BUD APAC (01876) target price to HK$8.7, cuts core net profit forecast by 10% to 13%
Citi lowers BUD APAC's 2026 to 2028 core net profit forecasts by 10%, 13%, and 11% respectively, and cuts its target price from HK$10.8 to HK$8.7.
Citi issued a research report stating that it has lowered the target price for BUD APAC (01876) from HK$10.8 to HK$8.7, maintained its "Buy" rating, and cut its core net profit forecasts for 2026 to 2028 by 10%, 13%, and 11% respectively, due to a 2% reduction in sales forecasts for each year, while taking a cautious view on the outlook for the second half of the year.
The bank lowered the target EV/EBITDA multiple for the West Asia Pacific business (with a heavier weighting in China) from 10x to 8x its 2026 forecast, in line with the East Asia Pacific region, to reflect continued industry weakness.
Citi reiterated its ranking order for China's beer industry as CHINA RES BEER (00291), BUD APAC, and Tsingtao Brewery (00168), all rated "Buy."
Related Articles

HK Stock Market Move | CRO concept stocks led the gains; JP Morgan said it is not too worried about the impact of rising interest rates on the sector, and order growth supports subsequent earnings delivery.

HK Stock Market Move | KUAISHOU-W(01024) rose over 3% in early trading; Kling AI is reported to plan a Hong Kong listing next year to raise at least US$1 billion.

JP Morgan: Not too worried about rising interest rates affecting China's healthcare industry; remains bullish on biotech and CXO.
HK Stock Market Move | CRO concept stocks led the gains; JP Morgan said it is not too worried about the impact of rising interest rates on the sector, and order growth supports subsequent earnings delivery.

HK Stock Market Move | KUAISHOU-W(01024) rose over 3% in early trading; Kling AI is reported to plan a Hong Kong listing next year to raise at least US$1 billion.

JP Morgan: Not too worried about rising interest rates affecting China's healthcare industry; remains bullish on biotech and CXO.






